Karen Sanders

发表

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

M. Parmar, M. Sydes, D. Dearnaley, 2009, The Lancet. Oncology.

A Trial of a Shorter Regimen for Rifampin‐Resistant Tuberculosis

A. Van Deun, K. Sanders, S. Meredith, 2019, The New England journal of medicine.

Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.

Bingshu E. Chen, M. Parmar, M. Sydes, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

M. Parmar, M. Sydes, R. Cowan, 2011, Lancet.

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

M. Parmar, M. Sydes, D. Dearnaley, 2012, The Lancet. Oncology.

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial

M. Parmar, M. Sydes, D. Dearnaley, 2012, Trials.

Randomised controlled trial to evaluate the effectiveness of using the RD-1-based C-Tb skin test as a replacement for blood-based interferon-γ release assay for detection of, and initiation of preventive treatment for, tuberculosis infection: RID-TB:Dx study protocol

R. Horne, P. Whiting, A. Crook, 2021, BMJ Open.

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi‐arm, multistage randomized controlled trial

John Dwyer, M. Sydes, D. Dearnaley, 2009, BJU international.

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

M. Parmar, M. Sydes, R. Cowan, 2011, Lancet.

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

M. Parmar, M. Sydes, D. Dearnaley, 2009, Trials.

Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised contro

R. Horne, A. Crook, K. Sanders, 2022, BMJ Open.

STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.

M. Parmar, M. Sydes, D. Dearnaley, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy

N. Beeching, M. Johnson, K. Sanders, 2016, AIDS.

Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis

J. Madan, A. Van Deun, K. Sanders, 2022, Trials.

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

M. Parmar, M. Sydes, R. Cowan, 2011, The Lancet.

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: First results from STAMPEDE (MRC PR08, CRUK/06/019), a randomized controlled trial.

M. Parmar, M. Sydes, D. Dearnaley, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

L. Rigouts, K. Sanders, M. Gurumurthy, 2022, The Lancet.

Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial

M. Parmar, M. Sydes, D. Dearnaley, 2011, Trials.

Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy

N. Beeching, M. Johnson, A. Clarke, 2016, AIDS.